Clinical Trial Update: Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating arsenic trioxide with pamidronate in patients with advanced solid tumors or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Pamidronate (pamidronate disodium)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED